Biogen, Sage

Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' best interests.
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.
Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.
Sage Therapeutics Explores Alternatives, Rejects Biogen's Proposal, Stock Up
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Monday announced that its Board of Directors has initiated a strategic review process aimed at maximizing shareholder value, involving a wide range of options, such as potential strategic transactions, business combinations, or the sale of the company.
Sage Sues Partner Biogen After Unsolicited Takeover Offer
Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital Markets.
Sage Therapeutics: Looks Like A 'Strong Buy' With Zurzuvae's Potential And Biogen's Bid
Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE stock is a good buy at these levels.
Sage Therapeutics initiates strategic review, rejects Biogen proposal
Sage Therapeutics (SAGE) announced that its board of directors has initiated a process to explore strategic alternatives for the company. The
Sage rejects Biogen's $469 million takeover offer
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The company said Biogen's offer to buy all outstanding shares of Sage that it does not already own for $7.
Sage Rejects Biogen Bid, Launches Review of Alternatives
Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal significantly undervalues the biopharmaceutical company and isn't in the best interest of its shareholders.
Sage Group falls Monday, underperforms market
Sage Group PLC SGE shares inched down 0.34% to £13.26 Monday, on what proved to be an all-around favorable trading session ...
FiercePharma6d
Sage sues Biogen as analyst detects little interest in buyout at original offer price
Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...
Lindsay Arnold Shares Daughter Sage's Hilarious Reaction to Her Implants Surgery: 'Wow Mom, They're Really Big'
Lindsay Arnold revealed how she explained her breast augmentation surgery to her daughters on Instagram Stories on Jan. 16.
‘Recalibrated’ Sage Hill girls basketball races past Portola to extend winning streak
Amalia Holguin, Addison Uphoff and Kamdyn Klamberg combine for 47 points as Sage Hill wins its sixth straight game.
TheGamer on MSN3d
Guide To Playing Sage In PvP In FFXIV
While you don't have all the multitude of skills Sage has in PvE, the core concept of the job is maintained in PvP. Although ...
Hosted on MSN2d
Sage Group Undertakes Share Buyback to Boost Shareholder Value
Sage Group plc ( ($GB:SGE) ) has issued an update. Sage Group plc has repurchased 389,944 of its ordinary shares as part of a share buyback ...
Sage Group rises Thursday, outperforms market
Sage Group PLC SGE shares inched up 0.26% to £13.37 Thursday, on what proved to be an all-around great trading session for ...